By Topic
Kaoko Metals (ASX: KAO): Broad Visual Copper Sparks Momentum, but Assays Still Hold the Key
Kaoko Metals is gaining attention after broad visible copper mineralisation at its Chalkos Project. With assays pending, drilling continuing and Donkey Hill still untested, upcoming exploration results could provide important clues about the project’s potential.
Black Cat Syndicate (ASX: BC8): Gold Production Surges as New High-Grade Discoveries Fuel Future Growth
Black Cat Syndicate (ASX: BC8) is a speculative mid-cap gold producer advancing Kal East, Paulsens, Coyote, and Mt Clement projects. Recent production growth, discoveries, and resource expansion support its long-term growth strategy.
Buru Energy (ASX: BRU): A Multi-Year Downtrend Meets Renewed Hope on New Project Funding
Buru Energy (ASX: BRU) is a pre-production explorer advancing its Rafael Gas Project toward a mid-2027 investment decision. Shares remain near 52-week lows, but funding progress, reserves certification, bullish divergence and trendline breakout potential offer catalysts amid significant dilution and execution risks.
BPM Minerals (ASX: BPM): Forelands Gold Project Momentum Sparks a Chart Breakout
BPM Minerals (ASX: BPM) is drilling its flagship Forelands Gold Project, targeting a maiden resource at Beachcomber. Shares broke out above $0.24 on strong volume, though the stock remains a speculative early-stage explorer dependent on upcoming assay results.
Critica (ASX: CRI): Recent Breakout Meets New Fundamental Signals From Mt Lindsay
Critica (ASX: CRI) released a Mt Lindsay Scoping Study showing a $1 billion NPV underground tin-tungsten operation, though shares eased on the day. With funding pathways still being explored, the company continues advancing its Jupiter rare earths project in parallel.
Has Neuren Pharmaceuticals' (NEU) share price bottomed out?
If you bought Neuren Pharmaceuticals (ASX: NEU) near its peak, the recent volatility has been uncomfortable. Despite having its first approved drug for a rare paediatric disorder, growing royalty income and a promising pipeline, the share price has repeatedly rallied and retraced over the past two years. The key question now is whether NEU has already formed a durable bottom — or if another leg down could still test investor conviction.
...